Medical Condition News

RSS

CAMD releases first combined clinical trial data on neuro-degenerative diseases

A new database of more than 4,000 Alzheimer's disease patients who have participated in 11 industry-sponsored clinical trials will be released today by the Coalition Against Major Diseases (CAMD). This is the first database of combined clinical trials to be openly shared by pharmaceutical companies and made available to qualified researchers around the world.

14 Jun 2010

New report provides state-by-state analyses of substance abuse, mental illness patterns

A new report providing state-by-state analyses of substance abuse and mental illness patterns reveals that despite wide variations among the states in the types and levels of behavioral health problems they experience -- every state suffers from these problems. For example, among those aged 12 and older, Iowa had less than one third the current illicit drug use rate of Rhode Island (4.1 percent vs. 13.3 percent) - yet Iowa's population aged 12 and older was among the group of states with the nation's highest levels of people participating in binge drinking in the past month (27.2 percent).

14 Jun 2010

Synexus invests in Doppler Ultrasound for 7 UK-based Dedicated Research Centres

Manchester-based Synexus, the world's largest multi-national company dedicated to the recruitment and running of clinical trials, has recently invested in Doppler Ultrasound equipment for each of its seven UK-based Dedicated Research Centres. After training for all Synexus' doctors, the facilities are now being used as part of the drive to recruit patients to a new diabetes study.

From AES - Accelerated Enrollment Solutions 14 Jun 2010

Researchers report 4 pillars of preventive medicine for AD

Although effective treatment for Alzheimer's disease has been slow to emerge, there has been substantial progress in identifying AD risk factors and developing treatments that might delay or prevent onset of the disease. In a Special Issue of the Journal of Alzheimer's Disease, "Basics of Alzheimer's Disease Prevention," researchers report on key findings that point towards possible significant interventions.

14 Jun 2010

Short period of sick leave before lumbar disk herniation surgery yields better results

Back pain and leg pain may be caused by lumbar disk herniation. It may be necessary to treat the condition by surgery, if it persists. Patients who have a short period of sick leave before the surgery are more satisfied with the result of the procedure than those who are off work sick longer. This is the conclusion of a thesis from the University of Gothenburg, Sweden.

14 Jun 2010

Evidence-based review of TBI in sport

Experts from Johns Hopkins Medicine hosted a press conference following a continuing medical education program on the epidemiology of head injury in professional football. The program was an evidence-based review of traumatic brain injury in the sport.

14 Jun 2010

Study finds survival disparities among patients with colorectal cancer

Disparities in cancer stage and treatment are the main reasons why Medicaid-insured and uninsured rectal cancer patients are twice as likely to die within five years as privately insured patients. That is the conclusion of a new study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. Because poorer survival among rectal cancer patients without private insurance is largely attributable to later cancer stage at diagnosis and inadequate treatment, disparities may be lessened through health care reform.

14 Jun 2010

UJI participates in project OPTIMI for early detection of depression

Treatments for mental illnesses are based on medicines and on therapies. Nevertheless it is not being done much to develop effective systems to prevent the appearance of such illnesses. In January starts the European initiative OPTIMI to contribute to the early detection of depression. The research group Labpsitec of the Department of Basic and Clinical Psychology and Psychobiology at the Universitat Jaume I of Castellón, takes part in the project with the design of evaluation strategies for people in situation of risk.

14 Jun 2010

Astrocytes involved in regulation of signalling between neurons: Study

Astrocytes are the most common type of cell in the brain and play an important role in the function of neurons - nerve cells. New research from the University of Gothenburg, Sweden, shows that they are also directly involved in the regulation of signalling between neurons.

14 Jun 2010

ARBs increase risk of cancer: Study

University Hospitals Case Medical Center cardiologists have uncovered new research showing an increased risk of cancer with a group of blood pressure medications known as angiotensin-receptor blockers (ARBs).

14 Jun 2010

National MS Society commits over $2.4M to support 7 CCSVI research projects

Over $2.4 million has been committed by the National MS Society (USA) and the MS Society of Canada to support 7 new research projects focusing on the role of CCSVI in MS.

14 Jun 2010

Researchers show personal factors play major role in deciding duration of sick leave

Patients, sick-listed for back and neck problems return to work at different rates despite having similar problems, and personal factors play a major role, reveals a thesis from the University of Gothenburg, Sweden.

14 Jun 2010

Study confirms impact of febrile neutropenia on chemotherapy delivery in NHL

Data presented at the 15th European Hematology Association (EHA) congress in Barcelona, highlights the impact of febrile neutropenia (FN) on chemotherapy delivery in non-Hodgkin lymphoma (NHL) patients. The IMPACT NHL study showed that unplanned hospitalisations, delays in chemotherapy and reductions of chemotherapy dose leading to suboptimal relative dose intensity (RDI) of chemotherapy were more frequent in patients who experienced FN than those who did not.

14 Jun 2010

Nexavar does not meet primary endpoint in Phase 3 NExUS trial for advanced NSCLC

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that the final analysis of the Phase 3 NExUS (NSCLC research Experience Utilizing Sorafenib) trial evaluating Nexavar® (sorafenib) tablets in patients with advanced non-squamous non-small cell lung cancer (NSCLC) showed that the study did not meet its primary endpoint of improving overall survival in the first-line setting.

14 Jun 2010

CTI announces AIFA approval for manufacture of pixantrone at NerPharMa facility

Cell Therapeutics, Inc. today announced that the Italian Medicines Agency ("AIFA"), the national authority responsible for drug regulation in Italy, has approved the facility at NerPharMa DS (a pharmaceutical manufacturing company belonging to Nerviano Medical Sciences Srl, in Nerviano, Italy) for the production of CTI's drug candidate pixantrone.

14 Jun 2010

Phase III study of REVLIMID for treating patients with multiple myeloma shows improvement in PFS

Celgene International Sàrl announced that data from the planned second interim analysis (median follow-up of 21 months) of a phase III, randomized, double-blind study of continuous REVLIMID (lenalidomide) for the treatment of elderly patients with newly diagnosed multiple myeloma show improvement in progression-free survival, the primary endpoint of the study.

14 Jun 2010

New SACS Instrument launched to assess and classify peristomal skin lesions

A new evidence-based instrument to assess and classify peristomal skin lesions was launched at the 2010 Joint Conference of the Wound, Ostomy and Continence Nurses Society and World Council of Enterostomal Therapists. The instrument, known as the SACS Instrument, represents the first content-validated instrument to objectively assess and classify peristomal lesions by type and location in relation to an individual's stoma.

14 Jun 2010

Telmisartan reduces hypertension, cardiovascular risk in ACE-intolerant patients: Boehringer Ingelheim

Telmisartan, an angiotensin receptor blocker, is one of the best researched drugs worldwide. It has been studied in clinical trials in more than 50,000 patients. Its positive safety profile has been confirmed also in a market exposure of 34.5 million patient years. Convincing safety data for patients with a high cardiovascular risk were collected in the three long-term outcome trials ONTARGET, PRoFESS and TRANSCEND which followed some of the patients for up to five years.

14 Jun 2010

Researchers find new way to prevent blindness caused by retinitis pigmentosa

Researchers at the University of Oklahoma Health Sciences Center have found a way to use a radical new type of gene therapy to prevent blindness caused by retinitis pigmentosa, giving hope to the estimated 100,000 Americans who suffer from this debilitating disease.

14 Jun 2010

Blood flow interruption during renal surgery can increase risk of chronic kidney disease

Interrupting the blood flow for more than 20 to 25 minutes during kidney cancer (http://www.mayoclinic.org/kidney-cancer/research.html) surgery leads to a greater risk for patients developing chronic kidney disease, a Mayo Clinic and Cleveland Clinic collaborative research team has found. The study was published today in the journal, European Urology.

14 Jun 2010